CytoDyn (CYDY) Non-Current Assets (2011 - 2026)
CytoDyn's (CYDY) quarterly Non-Current Assets came in at $59000.0 in Q1 2026, down 71.5% YoY from $207000.0 in Q1 2025, and down 38.54% on a QoQ basis from $96000.0 in Q4 2025.
CytoDyn (CYDY) Non-Current Assets (2011 - 2026) Analysis & Trends
CytoDyn (CYDY) has 16 years of Non-Current Assets data on file, last reported at $59000.0 in Q1 2026.
- Quarterly Non-Current Assets fell 71.5% year-over-year to $59000.0 in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $457000.0 (down 56.68% YoY) and the FY2025 annual result came in at $169000.0, down 47.35% from the prior year.
- Non-Current Assets eased to $59000.0 in Q1 2026, from $96000.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $18.7 million in Q2 2022 to a low of $59000.0 in Q1 2026.
- A 5-year average of $2.5 million and a median of $360000.0 in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets surged 748.76% — and 2023, when it tumbled 97.61%.
- Tracing CYDY's Non-Current Assets over 5 years: stood at $523000.0 in 2022, then fell by 23.52% to $400000.0 in 2023, then slumped by 39.0% to $244000.0 in 2024, then slumped by 60.66% to $96000.0 in 2025, then plunged by 38.54% to $59000.0 in 2026.
- The last three Non-Current Assets figures came in at $59000.0 (Q1 2026), $96000.0 (Q4 2025), and $133000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - | 59,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 59,000.00 |
| Nov 30, 2025 | 96,000.00 |
| Aug 31, 2025 | 133,000.00 |
| May 31, 2025 | 169,000.00 |
| Feb 28, 2025 | 207,000.00 |
| Nov 30, 2024 | 244,000.00 |
| Aug 31, 2024 | 283,000.00 |
| May 31, 2024 | 321,000.00 |
| Feb 29, 2024 | 360,000.00 |
| Nov 30, 2023 | 400,000.00 |
| Aug 31, 2023 | 443,000.00 |
| May 31, 2023 | 487,000.00 |
| Feb 28, 2023 | 532,000.00 |
| Nov 30, 2022 | 523,000.00 |
| Aug 31, 2022 | 18.54 Mn |
| May 31, 2022 | 18.67 Mn |
| Feb 28, 2022 | 1.73 Mn |
| Nov 30, 2021 | 1.89 Mn |
| Aug 31, 2021 | 2.18 Mn |
| May 31, 2021 | 95.98 Mn |